Repeat Preeclampsia Testing Not Tied to Better Perinatal Outcomes

No benefit seen for stillbirth, early neonatal death, or neonatal unit admission
Repeat Preeclampsia Testing Not Tied to Better Perinatal Outcomes
Adobe Stock
Medically Reviewed By:
Meeta Shah, M.D.

TUESDAY, Feb. 27, 2024 (HealthDay News) -- Repeat placental growth factor (PlGF) testing in pregnant women with suspected preeclampsia is not associated with improved perinatal outcomes, according to a study published online Feb. 8 in The Lancet.

Alice Hurrell, from King's College London, and colleagues assessed whether repeat PlGF-based testing reduces adverse perinatal outcomes in pregnant individuals with suspected preterm preeclampsia. The analysis included 1,253 women with suspected preeclampsia (between 22 weeks and 0 days of gestation and 35 weeks and 6 days of gestation).

The researchers found no significant difference in the primary perinatal composite outcome (stillbirth, early neonatal death, or neonatal unit admission) between revealed repeat PlGF-based testing (31.2 percent) versus concealed repeat PlGF-based testing with usual care (27.8 percent; relative risk, 1.21; 95 percent confidence interval, 0.95 to 1.33). There were four serious adverse events in the revealed repeat PlGF-based testing group and six in the concealed repeat PlGF-based testing group, all deemed unrelated to the intervention.

"In a high-income setting with a low prevalence of adverse outcomes, universal, routine repeat PlGF-based testing of all individuals with suspected pre-eclampsia is not recommended," the authors write.

One author disclosed ties to Revvity, QuidelOrtho, and Roche.

Abstract/Full Text

Editorial (subscription or payment may be required)

Related Stories

No stories found.